Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Publication Date: November 1, 2021

The Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy guideline, developed by the American Society of Clinical Oncology, provides evidence-based recommendations for the management of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitor (ICPi) therapy.

Questions

Minutes Est.

320

Possible Points

Unrated

Difficulty

Objectives

Recognizing symptoms of irAEs in patients receiving ICPi therapy
Understanding the time to onset of irAEs in patients receiving ICPi therapy
Identifying appropriate treatment approaches for grade 1 toxicities in patients receiving ICPi therapy
Learning management strategies for grade 2 toxicities in patients receiving ICPi therapy
Understanding treatment options for grade 3 toxicities in patients receiving ICPi therapy
Recognizing management principles for grade 4 toxicities in patients receiving ICPi therapy

Instructions

Answer All QuestionsYou must answer each question to move forward.

Get Instant FeedbackAfter you submit each answer, you'll receive an explanation.

Progress is Saved AutomaticallyYour progress is saved as you go, so you can stop and return to the quiz anytime.

Compare Your ResultsSee how your performance compares with your peers after each answer is submitted.

Earn PointsPoints are awarded for each correct answer.

Members Only FeaturesIf you're a member, you can track your progress and view the quizzes you've completed.